News coverage about Halyard Health (NYSE:HYH) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Halyard Health earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 47.2653375436932 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

Shares of Halyard Health (NYSE HYH) traded up 0.10% during trading on Friday, hitting $41.31. The stock had a trading volume of 274,902 shares. Halyard Health has a 52 week low of $31.59 and a 52 week high of $43.78. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of 39.72 and a beta of 1.78. The firm has a 50 day moving average price of $40.17 and a 200-day moving average price of $38.81.

Halyard Health (NYSE:HYH) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.14. The company had revenue of $399.20 million during the quarter, compared to analysts’ expectations of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter last year, the business posted $0.45 EPS. On average, equities research analysts forecast that Halyard Health will post $1.98 EPS for the current fiscal year.

HYH has been the topic of several recent analyst reports. Zacks Investment Research raised Halyard Health from a “sell” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Wednesday, May 3rd. TheStreet lowered Halyard Health from a “b-” rating to a “c” rating in a research report on Wednesday, May 3rd. BidaskClub raised Halyard Health from a “hold” rating to a “buy” rating in a research report on Wednesday, June 28th. Stephens raised Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Finally, Deutsche Bank AG upped their target price on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Halyard Health currently has a consensus rating of “Buy” and an average price target of $42.25.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/halyard-health-nysehyh-earning-somewhat-positive-news-coverage-study-shows/1479899.html.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Insider Buying and Selling by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.